{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:17:49Z","timestamp":1791973069694,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11899-021-00657-x","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T07:02:31Z","timestamp":1636009351000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-1920","authenticated-orcid":false,"given":"Michael G.","family":"Douvas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara L.","family":"Riegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"657_CR1","unstructured":"American Cancer Society, Cancer facts and figures, 2021, p.4. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2021\/cancer-facts-and-figures-2021.pdf."},{"issue":"29","key":"657_CR2","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1200\/JCO.20.00493","volume":"38","author":"SB Dixon","year":"2020","unstructured":"\u2022 Dixon SB, Chen Y, Yasui Y, Pui C-H, Hunger SP, Silverman LB, et al. Reducing morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2020;38(29):3418\u201329. https:\/\/doi.org\/10.1200\/JCO.20.00493. This retrospective trial shows that long-term risks of therapy are less in de-escalated treatment regimens in clinical situations where high extant cure rates allow this.","journal-title":"J Clin Oncol"},{"key":"657_CR3","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/S352-3026(19)30050-X","volume":"6","author":"DA Mulrooney","year":"2019","unstructured":"Mulrooney DA, Hyun G, Ness KN, Bhakta N, Pui C-H, Erhardt MJ, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Hematol. 2019;6:e306\u201316. https:\/\/doi.org\/10.1016\/S352-3026(19)30050-X.","journal-title":"Lancet Hematol"},{"issue":"11","key":"657_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1001\/jama.297.11.1207","volume":"297","author":"N Hijiya","year":"2007","unstructured":"Hijiya N, Hudson MH, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297(11):1207\u201315. https:\/\/doi.org\/10.1001\/jama.297.11.1207.","journal-title":"JAMA"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1200\/EDBK_100015","volume":"38","author":"S Armenian","year":"2018","unstructured":"Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. AM Soc Cli Oncol Educ Book. 2018;38:275\u2013300. https:\/\/doi.org\/10.1200\/EDBK_100015.","journal-title":"AM Soc Cli Oncol Educ Book"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:1\u201311. https:\/\/doi.org\/10.1136\/bmj.b4606.","journal-title":"BMJ"},{"issue":"29","key":"657_CR7","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1200\/JCO.2013:49.3205","volume":"31","author":"GT Armstrong","year":"2013","unstructured":"Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673\u201380. https:\/\/doi.org\/10.1200\/JCO.2013:49.3205.","journal-title":"J Clin Oncol"},{"issue":"67","key":"657_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","volume":"3","author":"P Jain","year":"2019","unstructured":"\u2022 Jain P, Kantarjian H, Boddu PC, Noguears-Gonzalez GM, Verstovsek S, Garcia-Manero G, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Advance. 2019;3(67):851\u201361. https:\/\/doi.org\/10.1182\/bloodadvances.2018025874. This study examines the longer term cardiovascular and arteriothrombotic impacts of targeted tyrosine kinase inhibitors used in both CML in which it is studied here and in Ph+ and Ph like ALL.","journal-title":"Blood Advance"},{"issue":"8","key":"657_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"BL Asselin","year":"2016","unstructured":"\u2022 Asselin BL, DevidaChen L, Franco VI, Pullen J, Borowitz MJ, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced stage lymphoblastic non-Hodgkin lymphoma: a report of the Children\u2019s Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34(8):854\u201362. https:\/\/doi.org\/10.1200\/JCO.2015.60.8851. This trial very well examines the short and longer term impacts of the cardioprotectant dexrazoxane in patients with acute lymphoblastic leukemia.","journal-title":"J Clin Oncol"},{"issue":"15","key":"657_CR10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMsa060185","volume":"355","author":"KC Oeffinger","year":"2006","unstructured":"Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572\u201382. https:\/\/doi.org\/10.1056\/NEJMsa060185.","journal-title":"N Engl J Med"},{"issue":"4","key":"657_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ecl.2020.07.001","volume":"49","author":"SA George","year":"2020","unstructured":"George SA, Effinger KE, Meacham LR. Endocrine sequelae in childhood cancer survivors. Endocrinol Metab Clin North Am. 2020;49(4):565\u201387. https:\/\/doi.org\/10.1016\/j.ecl.2020.07.001.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"657_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/17446651.2019.1561271","volume":"14","author":"P Bruzzi","year":"2019","unstructured":"Bruzzi P, Bigi E, Predieri B, et al. Long-term effects on growth, development, and metabolism of ALL treatment in childhood. Expert Rev Endocrinol Metab. 2019;14(1):49\u201361. https:\/\/doi.org\/10.1080\/17446651.2019.1561271.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"15","key":"657_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/archinternmed.2009.209","volume":"169","author":"LR Meacham","year":"2009","unstructured":"Meacham LR, Sklar CA, Li S, et al. Diabetes mellitus in long-term survivors of childhood cancer: increased risk associated with radiation therapy A Report for the Childhood Cancer Survivor Study (CCSS). Arch Intern Med. 2009;169(15):1381\u20138. https:\/\/doi.org\/10.1001\/archinternmed.2009.209.","journal-title":"Arch Intern Med"},{"issue":"2","key":"657_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000493943","volume":"91","author":"W Chamaitilly","year":"2019","unstructured":"Chamaitilly W, Sklar CA. Childhood cancer treatments and associated endocrine late effects: a concise guide for the pediatric endocrinologist. Horm Res Paediatr. 2019;91(2):74\u201382. https:\/\/doi.org\/10.1159\/000493943.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"657_CR15","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/S1470-2045(20)30595-7","volume":"22","author":"RL Mulder","year":"2021","unstructured":"Mulder RL, Font-Gonzalez A, van Dulmen-den BE, et al. Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e68\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(20)30595-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"657_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/AOG.0000000000000905","volume":"126","author":"E Elgindy","year":"2015","unstructured":"Elgindy E, Sibai H, Abdelghani A, Mostafa A. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126(1):187\u201395. https:\/\/doi.org\/10.1097\/AOG.0000000000000905.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"657_CR17","doi-asserted-by":"publisher","first-page":"E252","DOI":"10.1542\/peds.2012-1420","volume":"132","author":"E Kasai-Yoshida","year":"2013","unstructured":"Kasai-Yoshida E, Ogihara M, Ozawa M, Nozaki T, Morino M, Manabe A, et al. Temporal lobe epilepsy with hippocampal sclerosis in acute lymphoblastic leukemia. Pediatrics. 2013;132(1):E252-256. https:\/\/doi.org\/10.1542\/peds.2012-1420.","journal-title":"Pediatrics"},{"key":"657_CR18","doi-asserted-by":"publisher","unstructured":"\u2022 Angiolillo AL, Schore RJ, Kairalla JA, et al. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk b-lymphoblastic leukemia: results from Children's Oncology Group AALL0932. J Clin Oncol. Published online January 7, 2021. https:\/\/doi.org\/10.1200\/JCO.20.00494. This trial is an example of the successful de-escalation of therapy in standard risk ALL patients without sacrificing outcomes.","DOI":"10.1200\/JCO.20.00494"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00657-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T05:14:03Z","timestamp":1644470043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00657-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"7 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Douvas and Lara Riegler declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article contains no studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}